2 - 4 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Serum or plasma
0.3 mL (Note: This volume does not allow for repeat testing.)
Red-top tube, sodium heparin tube, potassium (EDTA) tube, or lithium (heparin) tube. Do not use a gel-barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant.
Separate serum from cells within 45 minutes of collection and transfer to a plastic transport tube. Separate plasma immediately and transfer to a plastic transport tube for shipment to the laboratory.
Collect samples immediately prior to next dose.
Hemolyzed samples; gel separator tubes; clotted specimen; samples not separated from blood cells
Homogeneous Enzyme Immunoassay
Therapeutic: 2.0−25.0 μg/mL
Topiramate is an anticonvulsant drug used as an adjunctive therapy in the treatment of patients with partial and secondary generalized epilepsy. Topiramate is a sulfamate-substituted monosaccharide, derived from D-fructose. The animal models suggest that topiramate exerts its anticonvulsant effect primarily by blocking the spread of seizures, rather than by elevating the seizure threshold. Pharmacokinetic studies in humans have shown that topiramate is absorbed rapidly, excreted largely unchanged in the urine.1 Carbamazepine and phenytoin can significantly induce the metabolism of topiramate, whereas valproic acid has only a slight influence on topiramate concentrations.2 The elimination half-life of topiramate is 18 to 23 hours and is dose-dependent; however, children, as differentiated from adults, can require at least a twofold increase in dose to achieve a comparable plasma level.3 The drug is approximately 15% protein bound. Although carbamazepine and phenytoin induce the metabolism of topiramate and shorten its half-life, topiramate has no significant effect on the plasma concentrations of these drugs or valproic acid. Maintenance doses of topiramate, given twice daily, range from 300−600 mg/day. Side effects include dizziness, reduced cognitive function, weight loss, and headache. As observed with many therapeutic agents, the interpatient variability in clinical response at similar topiramate plasma concentration can be appreciable. Differences in plasma levels between responders, nonresponders, and seizure-free patients can be indiscernible.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|716285||Topiramate (Topamax), Serum||17713-9||716288||Topiramate, Serum||ug/mL||17713-9|
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf